The Use of DPP-4 Inhibitors in Short Bowel Syndrome
Status:
Terminated
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
The inhibition of Dipeptidyl peptidase-4 should increase the concentration of glucagone-like
peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of
the intestine.
Phase:
Phase 4
Details
Lead Sponsor:
Stanley Dudrick's Memorial Hospital
Treatments:
Dipeptidyl-Peptidase IV Inhibitors Sitagliptin Phosphate